|Table of Contents|

The efficacy and safety of alternative intravesical instillation of BCG and pseudomonas aeruginosa to prevent recurrence of high-risk non-muscular invasive bladder cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 05
Page:
890-894
Research Field:
Publishing date:

Info

Title:
The efficacy and safety of alternative intravesical instillation of BCG and pseudomonas aeruginosa to prevent recurrence of high-risk non-muscular invasive bladder cancer
Author(s):
ZHANG Mengfei; ZHAO Qiuxiang; SUN Nannan; WANG He; FU Qiang
Department of Urology, Second Hospital of Air Force Medical University，Shaanxi Xi'an 710038,China.
Keywords:
pseudomonas aeruginosa; BCG vaccine; bladder perfusion; high-risk non-muscular invasive bladder cancer; gemcitabine
PACS:
R737.14
DOI:
10.3969/j.issn.1672-4992.2023.05.020
Abstract:
Objective:To analyze the effect of alternative intravesical instillation of bacillus calmette guerin（BCG) and pseudomonas aeruginosa（PA)-MSHA on the tumor recurrence rate,adverse reactions and quality of life of patients with high-risk non-muscular invasive bladder cancer（NMIBC) after operation.Methods:120 patients diagnosed as bladder cancer and treated with transurethral resection of bladder tumor（TURBT) from October 2017 to October 2019 in our department were retrospectively analyzed,and the postoperative pathology showed that they were high-risk NMIBC.They were randomly divided into two groups：BCG and PA-MSHA alternating perfusion group（experimental group,60 cases) and gemcitabine single drug perfusion group（control group,60 cases).The patients were followed up at different stages two years after operation,and the recurrence rate,adverse reactions and the impact on the quality of life of the patients before and after perfusion were compared and analyzed.Results:After 12 months of perfusion treatment,there was no significant difference in the recurrence rate between the two groups（P>0.05).At 18 and 24 months of perfusion,the recurrence rate of the experimental group（11.67%,15.00%) was lower than that of the control group（26.67%,33.33%),and the difference was statistically significant（P＜0.05).The experimental group had fewer adverse reactions after alternative perfusion of PA-MSHA,with the incidence of fever（1.30%),nausea and vomiting（0.40%),bladder irritation symptoms（3.70%),hematuria（0.40%),and the control group had fever（3.15%),nausea and vomiting（0.90%),bladder irritation symptoms（13.52%),and hematuria（1.10%).There was significant difference in the incidence of fever and bladder irritation（P＜0.05),but there was no significant difference in the incidence of nausea and vomiting and hematuria（P>0.05).The scores of quality of life in the experimental group at 12 and 24 months after treatment were higher than those in the control group,and the difference was statistically significant（P＜0.05).Conclusion:BCG and PA-MSHA alternative intravesical perfusion after high-risk NMIBC surgery can effectively prevent tumor recurrence,reduce the incidence of poor intravesical perfusion induction,and improve the tolerance and quality of life of patients.

References:

［1］SUNG HYUNA,FERLAY JACQUES,SIEGEL REBECCA L,et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA：A Cancer Journal for Clinicians,2021,71(3)：209-249.
［2］李辉章,郑荣寿,杜灵彬,等.中国膀胱癌流行现状与趋势分析［J］.中华肿瘤杂志,2021,43(3):293-298. LI HZ，ZHENG RS，DU LB，et al.Bladder cancer incidence,mortality and temporal trends in China［J］.Chinese Journal of Oncology,2021,43(3):293-298.
［3］甘廷彬,苟欣,何卫阳.非肌层浸润性膀胱癌灌注治疗新进展［J］.临床泌尿外科杂志,2016,31(2):180-184. GAN TB,GOU X，HE WY.New progress in instillation therapy for non-muscle-invasive bladder cancer［J］.Journal of Clinical Urology,2016,31(2):180-184.
［4］李亚伟,黄后宝,卓栋,等.经尿道海博刀黏膜下剥离整块切除非肌层浸润性膀胱癌的初步研究［J］.临床泌尿外科杂志，2018,33（11）：870-873. LI YW,HUANG HB，ZHUO D,et al.Transurethral endoscopic submucosal en-bloc resection of non-muscle-invasive bladder cancer with Hybrid knife:initial experience［J］.Journal of Clinical Urology,2018,33(11):870-873.
［5］汤小虎,陈焱.TURBT治疗早期非肌层浸润性膀胱癌的效果分析［J］.癌症进展,2016,14(10):1013-1015. TANG XH,CHEN Y.Effect of TURBT in the treatment of early non-muscle-invasive bladder cancer［J］.Oncology Progress,2016,14(10):1013-1015.
［6］任利翔,柴宝山.非肌层浸润性膀胱癌的灌注化学疗法研究进展［J］.中国药师,2016,19(9):1747-1751. REN LX,CHAI BS.Research progress in intravesical chemotherapy for non-muscle-invasive bladder cancer［J］.China Pharmacist,2016,19(9):1747-1751.
［7］王俞,李煜罡.经尿道膀胱肿瘤电切术后辅助膀胱热灌注化疗的应用进展［J］.临床肿瘤学杂志,2016,21(6):560-563. WANG Y,LI YG.Application progress of bladder hyperthermic perfusion chemotherapy after transurethral resection of bladder tumor［J］.Chinese Clinical Oncology,2016,21(6):560-563.
［8］中国肿瘤医院泌尿肿瘤协作组.非肌层浸润性膀胱癌膀胱灌注治疗专家共识(2021版)［J］.中华肿瘤杂志,2021,43(10):1027-1033. Urological Chinese Oncology Group.Expert consensus on intravesical therapy for non-muscle invasive bladder cancer（2021 edition)［J］.Chinese Journal of Oncology,2021,43(10):1027-1033.
［9］THYAVIHALLY YB，DEV P，WAIGANKAR S，et al.Intravesical bacillus calmette-guerin（BCG) in treating non-muscle invasive bladder cancer-analysis of adverse effects and effectiveness of two strains of BCG（Danish 1331 and Moscow-I)［J］.Asian Journal of Urology,2022,9（2):157-164.
［10］陈保春,田龙江,刘利峰,等.吉西他滨灌注联合2 μm激光治疗非浸润性膀胱癌的疗效及对相关标志物的影响［J］.现代肿瘤医学,2022,30(8):1421-1424. CHEN BC,TIAN LJ,LIU LF,et al.Effect of gemcitabine perfusion combined with 2 μm laser in the treatment of non-invasive bladder cancer and its influence on related markers ［J］.Modern Oncology,2022,30(8):1421-1424.
［11］MESSING EDWARD M,TANGEN CATHERINE M,LERNER SETH P,et al.Effect of intravesical instillation of gemcitabine vs Saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence：swog s0337 randomized clinical trial［J］.JAMA,2018,319(18)：1880-1888.
［12］SARI MOTLAGH REZA,PRADERE BENJAMIN,MORI KEIICHIRO，et al.Bladder-preserving strategies for bacillus calmette-guérin unresponsive non-muscle invasive bladder cancer；where are we and what will be expected［J］.Current Opinion in Urology,2020,30(4)：584-593.
［13］MARCUS J DANIELS,EMILY BARRY,NIV MILBAR,et al.An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer［J］.Urologic Oncology：Seminars and Original Investigations,2020,38(2)：40.e17-40.e24.
［14］GEORGIOS GAKIS,HARMAN M BRUINS,RICHARD CATHOMAS,et al.European association of urology guidelines on primary uethral carcinoma-2020 update［J］.European Urology Oncology,2020,3(4)：424-432.
［15］唐溯,刘菊,潘科锦,等.治疗用卡介苗在膀胱癌预防及治疗中的作用［J］.中国生物制品学杂志,2019,32(10):1092-1096. TANG S，LIU J，PAN KJ，et al.Therapy and prevention of bladder cancer by bacillus calmette-guerin vaccine for treatment［J］.Chinese Journal of Biologicals,2019,32(10):1092-1096.
［16］ZHAO XM，PAN SY,HUANG QL,et al.PA-MSHA in combination with EGFR tyrosine kinase inhibitor：A new strategy to overcome the drug resistance of non-small cell lung cancer cells［J］.Oncotarget,2016,7(31)：49384-49396.
［17］王健,彭辉,吴鹏,等.铜绿假单胞菌膀胱灌注对于治疗膀胱癌的疗效分析［J］.空军医学杂志,2018,34(6):415-418. WANG J,PENG H,WU P,et al.Intravesical instillation of pseudomonas aeruginosa for bladder cancer［J］.Medical Journal of Air Force,2018,34(6):415-418.
［18］LIU JJ，DUAN XY.PA-MSHA induces apoptosis and suppresses metastasis by tumor associated macrophages in bladder cancer cells［J］.Cancer Cell International,2017,17(1)：76.

Memo

Memo:
National Natural Science Foundation of China（No.81772745）;国家自然科学基金面上项目（编号：81772745）；陕西省重点研发计划一般项目—社会发展领域基金（编号：2020SF-124）
Last Update: 2023-01-31